Abstract
The anti-tumor activity of [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) on the MXT-M-3,2 breast cancer implanted into B6D2F1 mice was not significantly reduced by splenectomy or co-administration of cyclosporine A. Neither did the use of T-lymphocyte-deficient NMRI (nu/nu) mice as hosts substantially influence its anti-tumor effect. Obviously, [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) does not act by an enhancement of the specific immune defense.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / immunology*
-
Cyclosporine / pharmacology
-
Female
-
Humans
-
Immunity / drug effects
-
Immunologic Factors / pharmacology*
-
Immunosuppressive Agents / pharmacology
-
Mice
-
Mice, Inbred Strains
-
Organoplatinum Compounds / pharmacology*
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
Transplantation, Heterologous
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents
-
Immunologic Factors
-
Immunosuppressive Agents
-
Organoplatinum Compounds
-
(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (II)
-
Cyclosporine